TN-CKE-RESTAURANTS
10.5.2021 15:02:12 CEST | Business Wire | Press release
CKE Restaurants Holdings, Inc., the parent company of Carl’s Jr. and Hardee’s , announced the opening of its 1,000th international restaurant in Madrid, Spain, as they continue to bring bold, craveable burgers and flavors to all corners of the globe. The opening marks a key milestone for the brand as it continues to expand its international footprint across Europe, the Americas, Asia, the Middle East, Australia and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510005062/en/
The opening of the new Carl’s Jr. restaurant in Madrid marks the 23rd restaurant in Spain. CKE is continuing to expand across the European market, all the while, delivering new, innovative customer experiences and a menu filled with its impossible-to-ignore flavors.
“The opening of the 1000th international location is a proud moment placing CKE in the top tier of global restaurant chains,” said CEO of CKE Restaurants Ned Lyerly. “Our momentum is building as we have plans to double our international presence in the next five years. We will accelerate growth by focusing on partnerships with exceptional franchise operators who share our vision of offering the most innovative, best tasting food in our industry!”
CKE continues to expand its presence across six continents and has maintained positive same store sales globally for nearly a decade. Earlier this year, the company hit other pivotal international milestones, including opening its 300th restaurant in Mexico; celebrating 40 years of business in the Middle East; expanding across Australia with a flagship restaurant opening in Sydney and later this summer the company will open a restaurant in Charles de Gaulle Airport centered around speed and convenience with a “Grab & Go” station, self-order kiosks and more.
“The 1,000th international restaurant is a major milestone for our company, and we’re thrilled to be able to continue providing guests around the world an iconic taste of California,” said Mike Woida, President of CKE International . “This new Carl’s Jr. location in Spain exemplifies CKE’s commitment to adapt to the consumer landscape and offer new experiences while maintaining craveable flavors.”
With culinary innovation at the forefront, CKE Restaurants will continue to introduce mouth-watering flavors that highlight their brands’ Chargrilled Angus Beef Burgers, crispy Hand-Breaded Chicken Tenders™, their iconic range of products that everyone knows and loves, and additionally CKE will create local adaptations that are region-specific, such as the Morita Burger in Mexico, Poutine in Canada, and more.
Follow Carl’s Jr. and Hardee’s on social media for the latest product news and promotional offers.
Twitter:
@CarlsJr
and @Hardees
Instagram:
@CarlsJr
and @Hardees
Facebook:
www.facebook.com/carlsjr
and www.facebook.com/hardees
About CKE Restaurants Holdings, Inc.
CKE Restaurants Holdings, Inc. (“CKE”), a privately held company based in Franklin, Tennessee, runs and operates Carl’s Jr. and Hardee’s, two beloved regional brands, known for one-of-a-kind premium and innovative menu items such as 100 percent Black Angus Thickburgers®, Made from Scratch™ Biscuits and Hand-Breaded Chicken Tenders™. With both a US and international footprint, Carl’s Jr. Restaurants LLC and Hardee’s Restaurants LLC have over 3,900 franchised or company-operated restaurants in 44 states and 40 foreign countries and U.S. territories. For more information about CKE, please visit www.ckr.com or its brand sites at www.carlsjr.com and www.hardees.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom